The New South Wales government has awarded $1.1 million to All G through the latest round of its Biosciences Fund, and announced a new $20 million funding program to support companies developing high-tech innovations in New South Wales.
The Biosciences Fund is a $4.75 million, competitive commercialisation program which supports New South Wales startups in biotechnology and life sciences to develop and bring technologies to market.
Grant recipients in the 2025/26 round included;
- All G – addressing the nutrition gap between infant formula, derived from cow milk, and human milk by replicating the composition and function of breast milk more closely.
- HydGene Renewables – developed a breakthrough biocatalyst technology that converts waste biomass into green hydrogen for producing key primary molecules at low cost, without fossil fuels.
- Number 8 Bio – identified a methane inhibitor molecule and delivery system to tackle the approximately 6 per cent of total carbon emissions created by the world’s 2.6 billion cattle and 1.2 billion sheep.
- Swan Genomics – developed a world-first DNA sequencing technology that is simpler and cheaper than conventional platforms, which can be deployed in regional hospitals, diagnostic labs, and field sites.
In December, All G established a joint venture with French lactoferrin producer, Armor Protéines, aiming to support production and commercialisation of its recombinant human and bovine lactoferrin in 2026. The company also announced it will conduct a series B raise in the next year, after drawing $10 million in convertible notes from new and existing investors.
All G stated the $1.1 million grant from the New South Wales Government Biosciences Fund will help advance the development of human milk proteins in Australia.
“The funding will support the next stage of our work on human beta-casein, helping move the technology from laboratory development toward proof-of-concept scale-up, regulatory readiness and future manufacturing,” the company stated on LinkedIn.
“Thank you to the Office of the New South Wales Chief Scientist & Engineer and the New South Wales Government for supporting biotechnology innovation in Australia.”
New funding pathways
The New South Wales government has also announced a new funding program to support companies developing high-tech innovations in the state – the Emerging Technologies Commercialisation Fund.
Recognising the economic return science and innovation brings to the state, the government has invested $20 million into the new multi-year initiative, aiming to broaden support for innovative young companies and boost local manufacturing capabilities.
Minister for Innovation, Science and Technology, Anoulack Chanthivong, said the Emerging Technologies Commercialisation Fund targets a well‑known gap in the innovation pipeline.
“Stemming from our Innovation Blueprint, the Emerging Technologies Commercialisation Fund targets the stage where promising technologies have early evidence but still need funding and support to mature into investable, scalable solutions,” said Chanthivong.
“The new fund does this through repayable grants that help de‑risk development and accelerate commercialisation outcomes.
“The New South Wales government is committed to providing ongoing support to innovative companies to solve real-world challenges, such as tonight’s recipients who are achieving landmark health, environmental and economic outcomes right on our doorstep,” he said.
The first round has a funding pool of $7 million, supporting projects with grants from $500,000 to $2 million. Preliminary applications are now open, and close 29 April. Head to chiefscientist.nsw.gov.au/etcf for guidelines and submissions.
